Ribo’s coronary artery disease filing highlights the next frontier for RNA-based cardiovascular drugs
Ribo’s RBD1119 Phase 2 filing could test whether siRNA drugs can reduce coronary artery disease risk without bleeding trade-offs.
How Eli Lilly and Company is positioning VERVE-102 at the center of cardiovascular gene editing
Can Eli Lilly and Company’s VERVE-102 transform cholesterol treatment through one-time gene editing? Explore the risks, data, and implications.
Why Abbott’s Ultreon 3.0 could reshape stent planning in complex coronary disease
AI can now guide coronary imaging in real time. Abbott’s Ultreon 3.0 puts precision PCI closer to routine clinical workflow.
Could Reflow Medical’s new Cora microcatheters fix a hidden pain point in complex PCI?
Find out how Reflow Medical’s Cora Flex and Cora Force launch could reshape complex coronary intervention workflows.
CorVista Health expands machine-learning diagnostics to INOCA with new ACC.26 poster data
CorVista Health presents machine-learned non-invasive INOCA detection data at ACC.26. Analysis of what this means for cardiology and women’s heart care. Read more.
Can Cleerly’s AI platform replace invasive IVUS? INVICTUS registry data suggest noninvasive parity
Cleerly’s INVICTUS registry shows AI-QCT matches IVUS in coronary plaque quantification. Read the clinical analysis.